health #Glp1ReceptorAgonists #Wegovy #Zepbound Zepbound beats Wegovy rival in 1st head-to-head weight loss study Global News Mon 4m read People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy. globalnews.ca Related stories bc Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs Prince George Citizen Sun 4m read
bc Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs Prince George Citizen Sun 4m read
BURST